Newsbenzinga
4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win
· Published
Article summary
4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.
An excerpt from the original article.
Comments —
Loading comments…